Document is current
Any future updates will be listed below
-
Authors
Safgren, Stephanie L.
Suman, Vera J.
Leon Ferre, Roberto A.
Kosel, Matthew L.
Stearns, Vered
Henry, N. Lynn
Denduluri, Neelima
Irvin, William
Ingle, James N.
Sideras, Kostantinos
Ames, Matthew M.
Reid, Joel M.
Loprinzi, Charles L.
Black, John L.
Weinshilboum, Richard M.
Goetz, Matthew P.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA133049)
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 9 February 2025
First Online: 27 February 2025
Declarations
:
: M.P.G. reports personal fees for CME activities from Research to Practice, Clinical Education Alliance, Medscape, and MJH Life Sciences; personal fees serving as a panelist for a panel discussion from Total Health Conferencing and Ideology, and personal fees for serving as a moderator for Curio Science, Consulting fees to Mayo Clinic from ARC Therapeutics, AstraZeneca, Biotheranostics, Blueprint Medicines, Lilly, Rna Diagnostics, Sanofi Genzyme, Seattle Genetics and Engage Health Media; and grant funding to Mayo Clinic from Lilly, Pfizer, Sermonix, Loxo, AstraZeneca, ATOSSA and Takeda. N.L.H has personal fees for consulting with AstraZeneca, and for royalties from Up-to-Date. R.M.W is a cofounder and stockholder in OneOme LLC. V.S. received research grants to institution from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology, and QUE Oncology, is the Chair, Data Safety Monitoring Board, AstraZeneca and receives non-financial support from Foundation Medicine Study Assays. The remaining authors declared no competing interests for this work.
